Sands Capital Management LLC Cuts Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Sands Capital Management LLC lessened its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 4.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,769,853 shares of the biopharmaceutical company’s stock after selling 173,632 shares during the period. Sands Capital Management LLC owned approximately 3.91% of Ultragenyx Pharmaceutical worth $113,397,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in RARE. Norges Bank purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth $35,765,000. Russell Investments Group Ltd. grew its position in Ultragenyx Pharmaceutical by 599.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 840,451 shares of the biopharmaceutical company’s stock valued at $25,281,000 after purchasing an additional 720,256 shares during the last quarter. GW&K Investment Management LLC grew its position in Ultragenyx Pharmaceutical by 139.0% during the 3rd quarter. GW&K Investment Management LLC now owns 1,150,169 shares of the biopharmaceutical company’s stock valued at $34,597,000 after purchasing an additional 668,881 shares during the last quarter. Frontier Capital Management Co. LLC bought a new stake in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $19,106,000. Finally, Aberdeen Group plc raised its holdings in Ultragenyx Pharmaceutical by 94.3% in the third quarter. Aberdeen Group plc now owns 973,656 shares of the biopharmaceutical company’s stock worth $29,288,000 after buying an additional 472,600 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Up 1.0%

Shares of Ultragenyx Pharmaceutical stock opened at $22.84 on Wednesday. Ultragenyx Pharmaceutical Inc. has a twelve month low of $18.41 and a twelve month high of $42.37. The company’s 50 day moving average is $23.10 and its 200 day moving average is $28.98. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -3.91 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The company had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The company’s revenue for the quarter was up 25.5% on a year-over-year basis. During the same period last year, the firm posted ($1.39) EPS. Sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on RARE shares. Bank of America dropped their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, January 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. Wedbush reiterated a “neutral” rating and set a $25.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Jefferies Financial Group decreased their price target on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research note on Tuesday, December 30th. Finally, Robert W. Baird lowered their price target on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Sixteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $68.29.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 54,404 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the completion of the sale, the chief executive officer owned 658,994 shares of the company’s stock, valued at $15,025,063.20. The trade was a 7.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Erik Harris sold 10,539 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $240,289.20. Following the sale, the executive vice president owned 89,515 shares of the company’s stock, valued at approximately $2,040,942. This trade represents a 10.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 104,958 shares of company stock worth $2,394,858. Company insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.